{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T14:55:53Z","timestamp":1775660153087,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1933-8","type":"journal-article","created":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T14:02:33Z","timestamp":1561212153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet\u2019s disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Ippei","family":"Miyagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Hanami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Fukuyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Kawabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,22]]},"reference":[{"key":"1933_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00002281-199401000-00007","volume":"6","author":"JD O\u2019Duffy","year":"1994","unstructured":"O\u2019Duffy JD. Behcet\u2019s disease. Curr Opin Rheumatol. 1994;6:39\u201343.","journal-title":"Curr Opin Rheumatol"},{"key":"1933_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3109\/s10165-010-0370-y","volume":"21","author":"S Iwata","year":"2011","unstructured":"Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, et al. Efficacy of combination therapy of anti-TNF-\u03b1 antibody infliximab and methotrexate in refractory entero- Behcet\u2019s disease. Mod Rheumatol. 2011;21:184\u201391.","journal-title":"Mod Rheumatol"},{"key":"1933_CR3","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/rheumatology\/kep126","volume":"49","author":"S Iwata","year":"2009","unstructured":"Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, et al. Effects of anti-TNF-alpha antibody infliximab in refractory entero- Behcet\u2019s disease. Rheumatology. 2009;49:1012\u20133.","journal-title":"Rheumatology"},{"key":"1933_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5217\/ir.2017.15.3.395","volume":"15","author":"N Inoue","year":"2017","unstructured":"Inoue N, Kobayashi K, Naganuma M, Hirai F, Ozawa M, Arikan D, et al. Long-term safety and efficacy of adalimumab for intestinal Beh\u00e7et\u2019s disease in the open label study following a phase 3 clinical trial. Intest Res. 2017;15:395\u2013401.","journal-title":"Intest Res"},{"key":"1933_CR5","doi-asserted-by":"publisher","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","volume":"95","author":"T Hibi","year":"2016","unstructured":"Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore). 2016;95:e3863.","journal-title":"Medicine (Baltimore)"},{"key":"1933_CR6","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.cgh.2014.08.042","volume":"13","author":"S Tanida","year":"2015","unstructured":"Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, et al. Adalimumab for the treatment of Japanese patients with intestinal Beh\u00e7et\u2019s disease. Clin Gastroenterol Hepatol. 2015;13:940\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1933_CR7","first-page":"1833","volume":"19","author":"JH Lee","year":"2013","unstructured":"Lee JH, Cheon JH, Jeon SW, Ye BD, Yang SK, Kim YH, et al. Efficacy of infliximab in intestinal Beh\u00e7et\u2019s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"1933_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67\u201374.","journal-title":"J Autoimmun"},{"key":"1933_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00535-013-0872-4","volume":"49","author":"T Hisamatsu","year":"2014","unstructured":"Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Beh\u00e7et\u2019s disease: indication of anti-TNF\u03b1 monoclonal antibodies. J Gastroenterol. 2014;49:156\u201362.","journal-title":"J Gastroenterol"},{"key":"1933_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5217\/ir.2013.11.3.155","volume":"11","author":"HW Lee","year":"2013","unstructured":"Lee HW, Kim WH, Cheon JH. The medical treatments of intestinal Behcet\u2019s disease: an update. Intest Res. 2013;11:155\u201360.","journal-title":"Intest Res"},{"key":"1933_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2017.377","volume":"33","author":"YE Park","year":"2018","unstructured":"Park YE, Cheon JH. Updated treatment strategies for intestinal Beh\u00e7et\u2019s disease. Korean J Intern Med. 2018;33:1\u201319.","journal-title":"Korean J Intern Med"},{"key":"1933_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/ibd.21313","volume":"17","author":"JH Cheon","year":"2011","unstructured":"Cheon JH, Han DS, Park JY, Ye BD, Jung SA, Park YS ea. Development, validation, and respomsiveness of a novel disease activity index for intestinal Behcet\u2019s disease. Inflamm Bowel Dis. 2011;17:605\u201313.","journal-title":"Inflamm Bowel Dis"},{"issue":"18","key":"1933_CR13","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.3748\/wjg.v18.i40.5771","volume":"28","author":"HJ Lee","year":"2012","unstructured":"Lee HJ, Kim YN, Jang HW, Jeon HH, Jung ES, Park SJ, et al. Correlations between endoscopic and clinical disease activity indices in intestinal Behcet\u2019s disease. World J Gastroenterol. 2012;28(18):5771\u20138.","journal-title":"World J Gastroenterol"},{"key":"1933_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-004-0033-4","volume":"4","author":"M Suzuki Kurokawa","year":"2004","unstructured":"Suzuki Kurokawa M, Suzuki N. Behcet\u2019s disease. Clin Exp Med. 2004;4:1\u201320.","journal-title":"Clin Exp Med"},{"key":"1933_CR15","unstructured":"[No author listed]. Criteria for diagnosis of Behcet\u2019s disease. International Study Group for Behcet\u2019s Disease. Lancet 1990;335:1078\u20131080."},{"key":"1933_CR16","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/ibd.21517","volume":"17","author":"YS Jung","year":"2011","unstructured":"Jung YS, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet\u2019s disease. Inflamm Bowel Dis. 2011;17:1594\u2013602.","journal-title":"Inflamm Bowel Dis"},{"key":"1933_CR17","doi-asserted-by":"publisher","first-page":"e004587","DOI":"10.1136\/bmjopen-2013-004587","volume":"4","author":"S Narum","year":"2014","unstructured":"Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open. 2014;4:e004587.","journal-title":"BMJ Open"},{"key":"1933_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00384-016-2728-x","volume":"32","author":"J Park","year":"2017","unstructured":"Park J, Cheon JH, Park YE, Lee YJ, Lee HJ, Park SJ, et al. Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Behcet\u2019s disease. Int J Color Dis. 2017;32:745\u201351.","journal-title":"Int J Color Dis"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1933-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T23:07:02Z","timestamp":1592694422000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1933-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,22]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1933"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1933-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,22]]},"assertion":[{"value":"25 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the University of Occupational and Environmental Health, Japan Ethics Committee following the Helsinki Declaration. This retrospective study was approved by the institutional review board, and the requirement to obtain informed consent was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y. Tanaka has received speaking fees and\/or honoraria from Daiichi-Sankyo, Astellas, Eli Lilly, Chugai, Sanofi, Abbvie, Pfizer, YL Biologics, Bristol-Myers, Glaxo-Smithkline, UCB, Mitsubishi-Tanabe, Novartis, Eisai, Takeda, Janssen, and Asahi-kasei and has received research grants from Mitsubishi-Tanabe, Bristol-Myers, Eisai, Chugai, Takeda, Abbvie, Astellas, Daiichi-Sankyo, Ono, MSD, and Taisho-Toyama.K. Nakano has received speaking fees from Astellas, UCB, Mitsubishi-Tanabe, and Eisai and has received research grants from Mitsubishi-Tanabe, Eisai, and Eli Lilly.S. Nakayamada received speaking fees and\/or honoraria from Bristol-Myers, Sanofi, Abbvie, Eisai, Eli Lilly, Chugai, Asahi-kasei, and Pfizer (less than $10,000 each) and also research grants from Mitsubishi-Tanabe, Takeda, Novartis, and MSD.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}